As to be expected NOXA expression plays a relatively restricted role in determining cell fate and tumor progression in the presence and absence of therapeutic treatments against LC [210–213], leukemias [214, 215], rhabdomyosarcoma [216, 217], PC [218], OC [219], colorectal cancer (CRC) [220, 221], melanoma [222] and MM [223]. This evidence concerns the gene PMAIP1 and leukemia.